Studies on adjuvants used with the most promising schistosomiasis vaccine antigens have shown that they effectively enhance CD4+ T-cell responses and IFN-γ production, both of which are crucial for protective immunity against parasitic infections. This evidence concerns the gene IFNG and schistosomiasis.